| Protocol No. | PI | Title |
|---|
| CALGB-100701 | Leslie Andritsos | Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant for High-Risk Chronic Lymphocytic Leukemia (CLL) |
| CALGB-20802 | Leslie Andritsos | Embedded Protocol to CALGB-100701 |
| AMC-053 | Robert Baiocchi | Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined with (R)ICE in Subjects with EBV and/or HHV-8 positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma |
| OSU-10029 | Don Benson, Jr | An Extension Study to Investigate the Safety and Durability of Clinical Activity of CAL-101 in Patients with Hematologic Malignancies |
| OSU-08191 | Don Benson, Jr | Immunologic Studies in Hematological Malignancies: Mechanisms of Action in Natural Killer Cell Targeting of Acute Leukemias |
| OSU-11102 | Don Benson, Jr | A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma |
| CALGB-9760 | Clara Bloomfield | Multidrug Resistance Studies in AML |
| CALGB-9862 | Clara Bloomfield | Molecular Features of Acute Lymphoblastic Leukemia |
| CALGB-8461 | Clara Bloomfield | Cytogenetic Studies in Acute Leukemia [Dr. Clara Bloomfield, National Study Chair] |
| CALGB-50303 | Kristie Blum | Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas |
| CALGB-60405 | Kristie Blum | Embedded companion to CALGB 50303: Pharmacogenomics in CALGB 50303. |
| CALGB-580603 | Kristie Blum | Embedded Companion to CALGB-50303: Evaluating the Prognostic Utility of PET Scanning in Lymphoma |
| OSU-10049 | Kristie Blum | A Phase II trial of panobinostat and lenalidomide in patients with relasped or refractory Hodgkins's Lymphoma |
| OSU-10052 | Kristie Blum | A Phase I, Dose-escalation Trial of Rituxan and Bendamustine in Combination with Bruton's Tyrosine Kinase Inhibitor, PCI-32765, in Patients with Relapsed Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Indolent non-Hodgkin's lymphoma |
| CALGB-50801 | Kristie Blum | Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma |
| CALGB-150805 | Kristie Blum | Embedded Companion Study to CALGB-50604 |
| CALGB-150903 | Kristie Blum | Embedded Companion study to CALGB-50801 |
| OSU-10075 | Kristie Blum | A Database for Patients with Non-Hodgkin's and Hodgkins's Lymphoma |
| CALGB-150913 | Kristie Blum | Embedded companion to CALGB-50803 |
| CALGB-50904 | Kristie Blum | RANDOMIZED PHASE II TRIAL OF OFATUMUMAB AND BENDAMUSTINE VS. OFATUMUMAB, BORTEZOMIB (NSC #681239, IND #58443) AND BENDAMUSTINE IN PATIENTS WITH UNTREATED FOLLICULAR LYMPHOMA |
| OSU-11015 | Kristie Blum | A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma
|
| CALGB-151005 | Kristie Blum | Embedded Companion to CALGB-50904 |
| OSU-11077 | Kristie Blum | An Open-Label, Single-arm, Phase I study of AEB071 (a Protein Kinase C Inhibitor) in Patients with CD79-mutant Diffuse Large B-Cell Lymphoma |
| SWOG-S1106 | Kristie Blum | A Randomized Phase II Trial of R-HCVAD/MTX/Ara-C Induction Followed by Consolidation with an Autologous Stem Cell Transplant vs. RBendamustine Induction Followed by Consolidation with an Autologous Stem Cell Transplant for Patients Less than or Equal to 65 Years of Age with Previously Untreated Mantle Cell Lymphoma |
| OSU-12017 | Kristie Blum | A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patinets with Relapse or Refractory Diffuse Large B-CellLymphoma (DLBCL) |
| ECOG-E1411 | Kristie Blum | Intergroup Randomized Phase II Four Arm Study In Patients > 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV> R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV-> LR) |
| OSU-10016 | William Blum | Phase I Study of Lenalidomide and Conventional Chemotherapy in Relapsed or Refractory Acute Myeloid Leukemia |
| SWOG-S0535 | William Blum | Phase II study of ATRA, Arsenic Trioxide and Gematuzumab Ozogamicin in pts with previously untreated high risk APL. |
| CALGB-20703 | William Blum | Embedded Companion Study to CALGB-10502 |
| CALGB-60604 | William Blum | Embedded companion to CALGB 10503: Busulfan PK in 10503 |
| CALGB-20602 | William Blum | Embedded companion to CALGB 10503;Correlative science in CALGB 10503 |
| OSU-05024 | Roger Briesewitz | Effect of Small Molecule Kinase Inhibitors on the Proliferation and Survival of Primary AML Cells Ex Vivo. |
| CALGB-70603 | John Byrd | Embedded Campanion Study to CALGB-10501 |
| CALGB-20601 | John Byrd | Embeded Companion Study to CALGB-10501 |
| CALGB-20702 | John Byrd | Embeded Campion Study to CALGB-10404 |
| OSU-05099 | John Byrd | Normal Spleen and Tonsil Tissue for Research Use. |
| OSU-05128 | John Byrd | Use of Red Cross Leukopacs as Source of Normal Human Cells for Research Use. |
| OSU-0017 | John Byrd | Chronic Lymphocytic Leukemia Research Consortium Human Subjects Protocol for Sample Collection |
| CALGB-20203 | John Byrd | Molecular Markers of Chronic Lymphocytic Leukemia. |
| OSU-12024 | John Byrd | A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
| OSU-12062 | John Byrd | A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients with Advanced Hematological Malignancies |
| OSU-11176 | John Byrd | A Long-Term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B cell Lymphoma and Chronic Lymphocytic Leukemia |
| OSU-1997CO194 | Michael Caligiuri | OSUCCC Leukemia Tissue Bank |
| CALGB-20206 | Michael Caligiuri | A Study of the Relationship Between Natural Killer Cell Recognition and Lysis of Autologous Leukemis Blasts and Clinical Outcome of Acute Myeloid Leukemia Patients Treated with Interleukin-2 |
| OSU-T9802 | Michael Caligiuri | The Arthur G. James Cancer Center, Hematologic Malignancy Tissue Storage Facility |
| OSU-05049 | Spero Cataland | Concurrent Cyclosporine and Plasma Exchange Therapy as Initial Therapy of Thrombotic Thrombocytopenic Purpura (TTP) |
| OSU-05050 | Spero Cataland | Standardized Therapy of Thrombotic Thrombocytopenic Purpura |
| OSU-09024 | Beth Christian | A phase I/II study of veltuzumab (IMMU-106, hA20), a humanized anti-CD20 monoclonal antibody, combined with milatuzumab (IMMU-115, hLL1), a humanized anti-CD74 monoclonal antibody, in relapsed and refractory B-cell non-Hodgkin's lymphoma |
| CALGB-150910 | Beth Christian | Embedded Companion to CALGB-50901 |
| CALGB-50901 | Beth Christian | A PHASE II TRIAL OF OFATUMUMAB (CALGB IND# 112390) IN PREVIOUSLY UNTREATED FOLLICULAR NON-HODGKIN¿S LYMPHOMA (NHL) |
| OSU-05041 | Albert de la Chapelle | Genetic Ancestry and its Implications in Cytogenetic and Molecular Abnormalities of Acute Myeloid Leukemia. |
| OSU-07087 | Albert de la Chapelle | Characterization of Potential Susceptibility Genes in Chronic Lymphocytic Leukemia (CLL) |
| CALGB-60402 | Steve Devine | Embedded companion to CALGB 100103: Busulfan Pharmacokinetics in Elderly Leukemic Patients in CALGB 100103 |
| OSU-0241 | Steve Devine | Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation (A National Marrow Donor Program Protocol). |
| OSU-0242 | Steve Devine | A Research Database for Hematopoietic Stem Cell Transplantation and Marrow Toxic Injuries (A National Marrow Donor Program Protocol). |
| OSU-10074 | Steve Devine | High Dose Chemotherapy with Autologous Stem Cell Rescue for Aggressive B Cell Lymphoma and Hodgkin Lymphoma in HIV-infected Patients |
| CALGB-100801 | Steve Devine | Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML |
| CALGB-151001 | Steve Devine | Embedded Companion Study to CALGB-100801 |
| OSU-11087 | Steve Devine | A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications |
| OSU-11088 | Yvonne Efebera | Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft versus Host Disease
|
| OSU-11052 | Yvonne Efebera | A Phase 1, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravenous Administration of RGI-2001 in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) |
| OSU-11004 | Yvonne Efebera | Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft vs. Host Disease(GVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Hematopoietic Stem Cell Transplantation (HSCT) |
| OSU-11002 | Yvonne Efebera | Assessment of MicroRNA Expression in Acute Graft-versus-Host Disease |
| OSU-09088 | Yvonne Efebera | A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma |
| OSU-12194 | Michael Grever | Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia
|
| OSU-11055 | Craig Hofmeister | A Randomized Study to Compare the Effect of Short- and Long-Term Schedules of Cryotherapy on the Incidence and Severity of Mucositis in High-Dose Melphalan
|
| OSU-11048 | Craig Hofmeister | A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Advanced Hematological Malignancies |
| OSU-09102 | Craig Hofmeister | A Phase I Study of AR-42 in Adult Patients with Advanced or Recurrent Hematologic Malignancies and Solid Tumors, for Which No Standard Therapy is Available |
| OSU-10115 | Craig Hofmeister | Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis |
| OSU-07012 | Craig Hofmeister | Retrospective Case-Control Study of the Effect of Statin use on Clinical Response to Autologous Stem Cell Transplantation in Myeloma Patients. |
| OSU-11163 | Samantha Jaglowski | A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma |
| OSU-12215 | Jeffrey Jones | An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton¿s Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion |
| OSU-11120 | Jeffrey Jones | Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL |
| OSU-12200 | Jeffrey Jones | A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 for Treatment of Relapsed Hairy Cell Leukemia |
| OSU-12123 | Jeffrey Jones | A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia |
| OSU-12142 | Jeffrey Jones | A Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma |
| OSU-10156 | Jeffrey Jones | Phase II study of lenalidomide to repair immune synapse response and humoral immunity in early-stage, asymptomatic chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with high-risk genomic features |
| OSU-10001 | Jeffrey Jones | Assessment of Hypersensitivity Reactions and Feasibility of a 60 Minute Rapid Infusion Rituximab Protocol at a Comprehensive Cancer Center |
| CALGB-150711 | Jeffrey Jones | Embedded Campanion Study to CALGB-50701 |
| OSU-07068 | Rebecca Klisovic | Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD |
| OSU-07069 | Rebecca Klisovic | Myeloproliferative Disorder Research Consortium (MPD-RC) Research Tissue Bank |
| OSU-12163 | Rebecca Klisovic | A Phase IIa, Single-Arm,Open-Label Study of MOR00208,a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL).
|
| OSU-06020 | Eric Kraut | An Evaluation of Qualitative Platelet Disorders in Patients with Inherited Disorders of Coagulation. |
| OSU-0025 | David Lucas | Drug Sensitivity & Apoptosis Studies in Hematologic Malignancies |
| OSU-12095 | Kami Maddocks-Christianso | A Phase 1b, Single-Arm, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination with Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia |
| OSU-11179 | Kami Maddocks-Christianso | A Phase I, Multi-center, Open-label Study of IMGN529 Administered Intravenously in Adult Patients with Relapsed or Refractory Non-Hodgkin¢¯s Lymphoma |
| OSU-11162 | Kami Maddocks-Christianso | A Pilot Two-Step Phase II Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Lymphoma (PLL) |
| OSU-11133 | Kami Maddocks-Christianso | A Phase 2 Study of the Bruton¿s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Genetic Risk-Stratified Relapsed and Refractory Patients with Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) and B-cell Prolymphocytic Leukemia (B-PLL) |
| CALGB-11001 | Guido Marcucci | A PHASE II STUDY INCORPORATING SORAFENIB (IND 69896, NSC 724772) INTO THE THERAPY OF PATIENTS ¡Ý 60 YEARS OF AGE WITH FLT3 MUTATED ACUTE MYELOID LEUKEMIA
|
| CALGB-361006 | Guido Marcucci | Embedded Companion to CALGB-11001 |
| CALGB-21003 | Guido Marcucci | Embedded Companion to CALGB-11001 |
| CALGB-21101 | Guido Marcucci | Embedded Companion to CALGB-11002 |
| CALGB-361101 | Guido Marcucci | Embedded Companion to CALGB-11002 |
| CALGB-211006 | Guido Marcucci | Embedded Companion to CALGB-11002 |
| CALGB-9665 | Guido Marcucci | Leukemia Tissue Bank [Dr. Michael Caligiuri, National Study Chair] |
| OSU-05061 | Guido Marcucci | Molecular Studies in Acute Myeloid Leukemia |
| OSU-05019 | Guido Marcucci | Assessment of Aberrant Expression of Leukemic Markers in Normal CD34+ Hematopoietic Precursors. |
| CALGB-20502 | Guido Marcucci | Molecular Genetic Studies of Acute Myeloid Leukemia (AML) with Normal Cytogenetics: A CALGB Leukemia Tissue Bank Project |
| CALGB-60706 | Guido Marcucci | Embeded Campanion Study to CALGB 10603 |
| CALGB-20202 | Guido Marcucci | Assessment of Novel Molecular Markers in Acute Myeloid Leukemia |
| OSU-12002 | Mitch Phelps | A PROSPECTIVE, DOUBLE-BLINDED, OBSERVATIONAL CLINICAL COHORT STUDY OF THE ASSOCIATION BETWEEN TACROLIMUS EXPOSURE AND CYP3A4, CYP3A5 GENOTYPES IN ADULT HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS |
| OSU-06083 | Christoph Plass | The Identification of Predisposing Genes in Chronic Lymphocytic Leukemia (CLL). |
| OSU-05075 | Pierluigi Porcu | A Retrospective Analysis of Clinical Presentation and Therapeutic Outcomes in T/NK-cell Lymphomas at the OSUCCC as a Benchmark for Future Translational Studies, Clinical Trial Design and Prediction of Accrual. |
| OSU-09073 | Pierluigi Porcu | Computer-aided Clinical Image Analysis for Cutaneous Lymphomas |
| OSU-09010 | Roger Ratcliff | An Investigation into Cognitive Deficits in Chemotherapy with Perceptual and Memory Tasks |
| OSU-12097 | Sumithira Vasu | A multicenter safety study of unlicensed investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients |
| OSU-11066 | Sumithira Vasu | KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor |
| OSU-11021 | Alison Walker | Research database for undiagnosed cytopenias. |
| OSU-09111 | Alison Walker | Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia |
| OSU-10081 | Alison Walker | A phase 1b, dose-finding study of oral panobinostat (LBH589) in combination with idarubicin and cytarabine induction and high-dose cytarabine-based consolidation therapy in adult patients less than or equal to 65 years old with acute myeloid leukemia (AML) |
| OSU-11013 | Katherine Walsh | A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate-2 or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) |
| OSU-09108 | Jennifer Woyach | A Phase I Feasibility/Phase II Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL) |